Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LIXT
stocks logo

LIXT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Lixte Biotechnology Holdings Inc (LIXT.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Lixte Biotechnology Holdings Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

LIXT News & Events

Events Timeline

(ET)
2025-11-25
08:42:25
Lixte Biotechnology purchases Liora's proton therapy technology.
select
2025-10-16 (ET)
2025-10-16
08:05:30
Lixte Biotechnology Shares Q4 Focus Areas and Development Progress Updates
select
2025-09-10 (ET)
2025-09-10
16:30:29
Lixte Biotechnology Acquires 10.5 Bitcoin and 300 Ethereum for $2.6 Million
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
11-25Newsfilter
LIXTE Acquires Liora Technologies to Advance Cancer Treatment Standards
  • Strategic Acquisition: LIXTE has acquired Liora Technologies Europe Ltd. for over $300 million, making it a wholly-owned subsidiary, marking the company's entry into the radiotherapy sector and advancing cancer treatment technologies.
  • Technological Advantage: The LiGHT system, installed at STFC's Daresbury Laboratory, offers high-precision proton therapy that is expected to significantly reduce treatment costs and increase patient capacity, potentially setting a new standard in cancer care.
  • Market Potential: CEO Pursglove stated that the LiGHT system has global market potential and could enable LIXTE to pursue a recurring revenue model through jointly operated treatment centers, enhancing the company's competitiveness in the cancer treatment market.
  • R&D Integration: This acquisition complements LIXTE's ongoing clinical trials with LB-100, further enriching the company's product line and supporting its innovative development in the field of cancer biology.
[object Object]
Preview
5.0
09-11NASDAQ.COM
Biotech Stocks Surge After Hours: Insider Purchases, Trial Progress, and Strategic Partnerships Drive Growth

  • Biotech Stocks Momentum: Several small-cap biotech stocks, including Nautilus Biotechnology and PepGen, are experiencing renewed investor interest due to insider buying, strategic partnerships, and clinical trial advancements, leading to notable after-hours gains.

  • Nautilus Biotechnology Highlights: Nautilus saw a significant rise in stock price following insider purchases by its CEO and a partnership with the Allen Institute, alongside a reported narrower loss and strong cash position.

  • Lixte Biotechnology's Financial Strategy: Lixte announced a $2.6 million investment in Bitcoin and Ethereum to diversify its treasury, reflecting a strategic shift aimed at enhancing flexibility in the digital economy.

  • RenovoRx and VolitionRx Developments: RenovoRx received positive feedback for its pancreatic cancer trial and is expanding commercialization efforts, while VolitionRx entered a partnership to advance its diagnostic technology for Antiphospholipid Syndrome.

[object Object]
Preview
1.0
08-27Yahoo Finance
LIXTE Unveils LB-100 at Inaugural Global Conference on Oncogenic Signaling Activation for Cancer Treatment in 24/7 Market News

  • New Publication on Cancer Treatment: A peer-reviewed manuscript in Trends in Cancer discusses the first international conference on activating oncogenic signaling as a cancer treatment strategy, co-sponsored by LIXTE Biotechnology Holdings.

  • Innovative Approach with LB-100: The conference highlighted LIXTE’s lead compound, LB-100, which activates oncogenic signaling to induce cancer cell death, representing a shift from traditional therapies that inhibit these pathways.

  • Therapeutic Potential of LB-100: Findings presented at the conference showed that LB-100 can hyperactivate growth pathways in tumors, leading to their toxicity and suggesting synergy with immunotherapy.

  • LIXTE's Leadership in Cancer Research: By organizing this landmark meeting, LIXTE positions itself as a thought leader in innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lixte Biotechnology Holdings Inc (LIXT) stock price today?

The current price of LIXT is 4.25 USD — it has increased 1.19 % in the last trading day.

arrow icon

What is Lixte Biotechnology Holdings Inc (LIXT)'s business?

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.

arrow icon

What is the price predicton of LIXT Stock?

Wall Street analysts forecast LIXT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIXT is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lixte Biotechnology Holdings Inc (LIXT)'s revenue for the last quarter?

Lixte Biotechnology Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Lixte Biotechnology Holdings Inc (LIXT)'s earnings per share (EPS) for the last quarter?

Lixte Biotechnology Holdings Inc. EPS for the last quarter amounts to -0.33 USD, decreased -25.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lixte Biotechnology Holdings Inc (LIXT)'s fundamentals?

The market is revising No Change the revenue expectations for LIXT for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -7.00%.
arrow icon

How many employees does Lixte Biotechnology Holdings Inc (LIXT). have?

Lixte Biotechnology Holdings Inc (LIXT) has 2 emplpoyees as of December 05 2025.

arrow icon

What is Lixte Biotechnology Holdings Inc (LIXT) market cap?

Today LIXT has the market capitalization of 26.29M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free